Cara Medical Receives FDA 510(k) Clearance for the CARA System for Noninvasive CTA based Cardiac Conduction System Visualization
February 25, 2026
TORTOLA, British Virgin Islands, Feb. 25, 2026 /PRNewswire/ — Cara Medical Ltd. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the CARA System, a computed tomography angiography (CTA)-based platform that provides noninvasive, patient-specific three-dimensional (3D) visualization of the cardiac conduction system.
